
## Masaru Kubota

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1854590/publications.pdf Version: 2024-02-01



MASADII KUBOTA

#	Article	IF	CITATIONS
1	Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respiratory Investigation, 2014, 52, 242-250.	1.8	208
2	Secular Changes in Relative Leg Length Confound Height-Based Spirometric Reference Values. Chest, 2015, 147, 792-797.	0.8	37
3	Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Cancer Management and Research, 2018, Volume 10, 6039-6047.	1.9	22
4	Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer. International Journal of Clinical Oncology, 2010, 15, 447-452.	2.2	17
5	<p>Impact of <em>EGFR </em>genotype on the efficacy of osimertinib in <em>EGFR </em>tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study</p> . Cancer Management and Research, 2019, Volume 11, 4883-4892.	1.9	17
6	Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report. Lung Cancer, 2016, 99, 66-68.	2.0	15
7	Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Investigational New Drugs, 2020, 38, 885-893.	2.6	12
8	Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensiveâ€disease small cell lung cancer in the elderly and patients with poor performance status. Thoracic Cancer, 2018, 9, 967-973.	1.9	11
9	Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring <b><i>EGFR</i></b> Mutations. Oncology, 2018, 95, 109-115.	1.9	10
10	Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. Cancer Management and Research, 2018, Volume 10, 7013-7019.	1.9	10
11	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. Oncology Research and Treatment, 2017, 40, 7-13.	1.2	9
12	A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 8695-8705.	1.9	8
13	Endobronchial involvement of mantle cell lymphoma: A case report. Respiratory Medicine Case Reports, 2016, 19, 77-79.	0.4	7
14	Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer. Investigational New Drugs, 2020, 38, 1906-1914.	2.6	7
15	Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer. Investigational New Drugs, 2017, 35, 642-648.	2.6	5
16	Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer. Cancer Management and Research, 2020, Volume 12, 4911-4921.	1.9	3
17	Statement on New Reference Values for Spirometry. Health Evaluation and Promotion, 2017, 44, 687-692.	0.0	0
18	MO272: Effect of the Hollow Fiber Diameter and Membrane Surface Area of the Polymethyl Methacrylate Membrane Filter Used in Continuous Renal Replacement Therapy on the Lifetime of the Filter. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0